We’re thrilled to share an update on our ongoing clinical trial! The first cohort is now fully enrolled, and we are actively preparing to open enrollment for the second cohort in April 2025.

For those who have contacted us about participation, please remember that we use a rolling list, so participants are contacted in the order we receive interest. If you haven’t been contacted yet, we appreciate your patience as we continue to work.

While we always seek donations to continue these trials, we’re also excited to share that we’ve submitted several grant applications to continue this critical research. With compounds like rapamycin, which already have established safety profiles and off-label use, we believe the potential to advance science and improve health is immense. We hope the NIH will recognize the importance of this work and support our efforts to bring these findings closer to clinical translation.

Thank you for your ongoing interest and support.

If you have questions about your application status or our next steps, feel free to reach out. We look forward to sharing more updates as we continue to make progress!